{"id":"W1997853067","doi":"10.1007/s10637-007-9097-9","title":"A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial","year":2007,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":93,"is_retracted":false,"has_abstract":false,"ca_institutions":"Juravinski Cancer Centre; BC Cancer Agency; Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre; Université de Montréal; Queen's University; Hôpital Notre-Dame","funders":"","keywords":"Medicine; Melanoma; Neutropenia; Adverse effect; Toxicity; Clinical trial; Internal medicine; Phases of clinical research; Cancer; Pharmacokinetics; Chemotherapy; Surgery; Oncology; Gastroenterology; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003680908,0.0002295059,0.0008824651,0.0002545761,0.0001204054,0.000005403379,0.0002367055,0.0001088715,0.0002883125],"category_scores_gemma":[0.001880529,0.0001594379,0.0001015269,0.000432499,0.0003162255,0.0001617238,0.00005017375,0.0002495171,0.000001843376],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001584861,"about_ca_system_score_gemma":0.005258607,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.05704433,"about_ca_topic_score_gemma":0.09794987,"domain_scores_codex":[0.9959598,0.0009986,0.002126779,0.000309613,0.0003224086,0.0002828278],"domain_scores_gemma":[0.9970725,0.001322588,0.001036967,0.0001817248,0.0003306508,0.00005553877],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8573648,0.03491444,0.02498228,0.0001146778,0.004218739,0.00002899327,0.006271905,0.0001759938,0.01293991,0.003043849,0.01103455,0.04490985],"study_design_scores_gemma":[0.7597958,0.04160896,0.1594645,0.0006141416,0.0004283211,0.00001193374,0.001121542,0.00001378858,0.0117735,0.0005981007,0.02381169,0.0007577036],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.995746,0.0007376855,0.00003945395,0.0002224442,0.001479306,0.001542475,0.0001910758,0.000008240471,0.00003333136],"genre_scores_gemma":[0.9984869,0.00001913191,0.0002649251,0.0002072271,0.00007216056,0.00006998241,0.0002255483,0.00001490443,0.0006392238],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1344822,"threshold_uncertainty_score":0.9492349,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08669226906530368,"score_gpt":0.3826761406183515,"score_spread":0.2959838715530478,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}